Arthritis Monoclonal Antibodies Global Market Report 2024

The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2023 to $62.29 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historical period can be attributed to several factors. These include the escalating prevalence of arthritis, heightened awareness regarding the efficacy of arthritis monoclonal antibodies, a widening array of approved medications in this category, governmental support for research and development initiatives, and increased investments from pharmaceutical companies within this domain.

The arthritis monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $83.76 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. Anticipated growth in the forecast period is expected due to several factors, including the adoption of combination therapies, the expansion of indications for these treatments, growing patient preferences, and an overall increase in healthcare expenditure.

The escalating global prevalence of arthritis, affecting over 350 million individuals, predominantly through osteoarthritis, gout, fibromyalgia, and rheumatoid arthritis, has notably boosted the arthritis monoclonal antibody market. In 2021, Rheumatoid arthritis spans 0.3% to 1% worldwide, while osteoarthritis affects approximately 9.6% of men and 18% of women. This surge in arthritis cases, coupled with a growing demand for personalized medicine, is fueling the market's growth.

The surge in approvals for personalized medicines is a significant driver propelling the arthritis monoclonal antibody market. Personalized medicines, tailored to individual patient characteristics, including genetic and biomarker profiles, are revolutionizing treatment responses. Monoclonal antibodies, representing this personalized medicine trend, have the potential to enhance patient outcomes significantly. Notably, in 2021, the FDA's CDER greenlit 35% of its 50 new molecular entities as personalized medicines, according to the Personalized Medicine Coalition, further catalyzing the arthritis monoclonal antibody market. The evolution of therapeutic monoclonal antibody products stands as a pivotal force in advancing the arthritis monoclonal antibody market. These highly efficient, target-specific antibodies excel in treating arthritis, surpassing small molecules and peptides. The market's expansion is evident through the introduction of a multitude of monoclonal antibody drugs dedicated to arthritis treatment, signifying enhanced therapeutic options.

Leading players in the arthritis monoclonal antibody market are introducing cost-effective biosimilar versions like Hulio to ensure more accessible treatment options. Hulio, a biosimilar variant of AbbVie's Humira, a prominent rheumatoid arthritis drug, was launched by Biocon Biologics in July 2023. Priced at a 5% discount to Humira, which currently stands at $6,922 per carton, Hulio caters to conditions like rheumatoid arthritis and psoriatic arthritis, aiming to make treatment more affordable.in May 2023, Abiogen Pharma Spa, an Italy-based pharmaceutical company, acquired EffRx Pharmaceuticals SA for $8.77 million. The acquisition of a majority stake in EffRx is consistent with Abiogen's growth strategy. It provides a springboard for their international expansion and affirms their dedication to improving osteoarticular and bone metabolism diseases. EffRx Pharmaceuticals SA is a Switzerland-based pharmaceutical company involved in treating various disorders, including arthritis.

Major companies operating in the arthritis monoclonal antibodies market include Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca PLC, Mylan N.V., Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.

North America was the largest region in the arthritis monoclonal antibodies market in 2023. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The arthritis monoclonal antibodies market consists of sales of infliximab, adalimumab, golimumab, and certolizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary types of drugs in this category include Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, and Remsima. Remicade, for instance, is prescribed for individuals with moderately to severely active Crohn's disease who haven't responded well to other treatments. These medications find application across various conditions such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, among others. Their utilization spans multiple sectors including hospitals, research institutes, and other healthcare domains.

The arthritis monoclonal antibodies market research report is one of a series of new reports provides arthritis monoclonal antibodies market statistics, including arthritis monoclonal antibodies industry global market size, regional shares, competitors with arthritis monoclonal antibodies market share, detailed arthritis monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the arthritis monoclonal antibodies industry. This arthritis monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.